FDA Approves TOBRADEX ST — Harrow Eye, LLC

# FDA Approves Harrow Eye's TOBRADEX ST for Ophthalmic Inflammation Harrow Eye, LLC has received FDA approval for TOBRADEX ST (tobramycin/dexamethasone), a combination ophthalmic anti-inflammatory and antibiotic treatment, positioning the company to capture market share in the competitive eye care segment. The approval strengthens Harrow Eye's ophthalmology portfolio and enables it to address the substantial patient population requiring post-operative and inflammatory eye condition management.